Status
Conditions
Treatments
About
It has been shown that patients with Parkinson's disease (PD) have impaired kinaesthesia and haptic perception of the upper limbs. In PD patients, these impairments might be involved in the development of hypometria or bradykinesia and may play a role in postural deficits, thereby significantly contributing to the overall disability level.
Dedicated conventional or robot-assisted training might improve sensory-motor function in PD patients. In order to provide efficient robot-assisted therapy, robotic devices have to be able to tailor the therapy difficulty to the individual impairment profile of each patient. For difficulty adaptation in robot-assisted therapy, it is important to assess the impairment profiles with the same robotic platform that would be used for therapy, therefore minimizing costs or potential errors coming from the use of different devices. However, up to now, little emphasis has been placed on providing sensory-motor robot-assisted therapy for the upper limbs to persons with PD based on their individual level of impairment.
The aim of this study is therefore to evaluate if the assessments of sensory-motor hand function implemented on a robotic device for hand rehabilitation, i.e. the ReHapticKnob, are suitable to measure the impairments of kinaesthesia and haptic perception observed in subjects with Parkinson's disease.
If the assessments implemented in the ReHapticKnob are sensitive enough to detect a difference between the sensory-motor function of PD patients and healthy subjects, the device might in the future be used to assess improvements before and after sensory-motor therapy. This is a necessary step before the investigators can use these assessments to tailor the difficulty level of the therapy performed with the ReHapticKnob and to investigate the benefits and impact of such a therapy on the kinaesthetic and haptic impairments of persons with PD.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Ten patients with Parkinson's disease and 10 age-matched control subjects will be recruited.
Patients with Parkinson's disease: inclusion criteria
Diagnosis of idiopathic Parkinson's disease according to UK Parkinson's disease society brain bank clinical diagnostic criteria
Age between 35 and 80 years
Hoehn and Yahr stage of I, II or III during the ON state
Montreal Cognitive Assessment (MoCA) ≥ 26
No tremor, i.e.:
The subject read, understood and signed the informed consent
Patients with Parkinson's disease: exclusion criteria
Control subjects: inclusion criteria
Control subjects: exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Giada Devittori, M. Sc.; Olivier Lambercy, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal